The role of molecular genetic factors in the development of the first episode and recurrent noncardioembolic ischemic stroke

Шишкова, В Н; Адашева, Т. В.; Стаховская, Л В; Ременник, А Ю; Valiaeva, Vera V.

doi:10.26442/20751753.2020.9.200324

2020

DOI: 10.26442/20751753.2020.9.200324

|View full text |Cite

The role of molecular genetic factors in the development of the first episode and recurrent noncardioembolic ischemic stroke

В Н Шишкова¹,

Т. В. Адашева²,

Л В Стаховская³

et al.

Abstract: Цель. Провести оценку распределения полиморфных аллелей генов APO A5 (rs34282181), APO A5 (rs619054), APO E (rs5174), APO C4 (rs1132899), АРО Н (rs4581), LPL (rs199675233), LP(a) (rs41267817), APO B (rs1042031), АРО В (rs676210), АРО D (rs7659), ANGPT4 (rs1044250), TNFа (rs1800620), VEGFA (rs62401172), IL8 (rs1803205), IL6 (rs56383910), MTHFR (rs1801131), MTHFR (rs1801133), ADIPOQ-AS1 (rs17366743), ADIPOQ-AS1 (rs185847354), ADIPOR2 (rs12342), GRM 1 (rs1047005), GRM 3 (rs2228595), BDNF (rs6265) для выявления ас… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The choice of a modern neuroprotective drug as a basic strategy in the treatment of chronic cerebrovascular diseases

2023

View full text Add to dashboard Cite

The topicality of the issues of effective treatment and prevention of cerebrovascular diseases (CVD) is not doubtful in view of their leadership in the top ranked causes of high mortality and disability in the general population almost all over the world, including Russia. The pathogenetic aspects of chronic CVD caused by hypoperfusion, which triggers a chain of successively developing metabolic disorders, represent a potential therapeutic target for the development of new dosage forms. The enormous clinical experience has been accumulated and evidence of therapeutic benefits in patients with various types of vascular and metabolic disorders accompanied by ischemia, including cerebrovascular disease, has been obtained over almost thirty years of active clinical use of ethylmethylhydroxypyridine succinate (6-methyl-2-ethylpyridin-3-ol butanedioate, EMHPS). It proved that EMHPS has such important effects as antioxidant, membrane-protective, antihypoxic, and anti-ischemic properties, as well as confirmed its hypoglycemic, hypolipidemic, antiplatelet and antithrombotic actions, which makes it an important component of the complex therapy of CVD. Progress in the development of innovative drugs is the result, on the one hand, of the availability of highly active pharmacological substances and, on the other hand, of the creation or selection of new dosage forms. The use of matrix tablets as a modern dosage form allowed us to efficiently optimize the pharmacokinetics of EMHPS, which led to the creation of a drug with a high predictive efficacy and safety. Thus, the developed new prolonged dosage form of EMHPS enables a constant-rate daily release of the active substance for 20 hours and reduces the likelihood of not only side effects, but also skipped intake during the day. The new dosage form of EMHPS is available at 375 and 750 mg doses, which makes it possible to take just 1 tablet per day and get all the therapeutic benefits while staying compliant.

show abstract

The choice of a modern neuroprotective drug as a basic strategy in the treatment of chronic cerebrovascular diseases

2023

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The role of molecular genetic factors in the development of the first episode and recurrent noncardioembolic ischemic stroke

Cited by 1 publication

References 0 publications

The choice of a modern neuroprotective drug as a basic strategy in the treatment of chronic cerebrovascular diseases

The choice of a modern neuroprotective drug as a basic strategy in the treatment of chronic cerebrovascular diseases

Contact Info

Product

Resources

About